Godsey & Gibb Inc’s AstraZeneca AZN Stock Holding History

Godsey & Gibb Inc’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14	Closed	-$2.07K	–	443
2025 Q3	$2.07K	Sell	14 -11	-44%	-$1.67K	﹤0.01%	343
2025 Q2	$3.42K	Sell	25 -58	-70%	-$8.13K	﹤0.01%	307
2025 Q1	$12.2K	Buy	83 +58	+232%	+$8.39K	﹤0.01%	267
2024 Q4	$3.21K	Hold	25	–	–	﹤0.01%	324
2024 Q3	$3.82K	Sell	25 -89	-78%	-$14.4K	﹤0.01%	378
2024 Q2	$17.7K	Sell	114 -3	-3%	-$451	﹤0.01%	260
2024 Q1	$15.8K	Sell	117 -261	-69%	-$34.6K	﹤0.01%	241
2023 Q4	$50.9K	Hold	378	–	–	0.01%	161
2023 Q3	$51.1K	Sell	378 -15	-4%	-$2.05K	0.01%	155
2023 Q2	$56.2K	Hold	393	–	–	0.01%	158
2023 Q1	$54.5K	Sell	393 -100	-20%	-$13.5K	0.01%	161
2022 Q4	$66.8K	Sell	493 -124	-20%	-$15.6K	0.01%	100
2022 Q3	$68K	Buy	+617	New	+$78.3K	0.05%	27

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Godsey & Gibb Inc's AZN Position: Q4 2025 in Review

Godsey & Gibb Inc sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 14 shares — an estimated $2.07K sold.

Godsey & Gibb Inc first reported a position in AZN in Q3 2022 and held it in 13 quarters. The position peaked at $68K in Q3 2022. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Godsey & Gibb Inc reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Godsey & Gibb Inc sold 14 AstraZeneca shares in Q4 2025, an estimated $2.07K.
Godsey & Gibb Inc first reported a position in AstraZeneca in Q3 2022 and held it in 13 quarters.
Godsey & Gibb Inc's AstraZeneca position peaked at $68K in Q3 2022.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Godsey & Gibb Inc's 13F filing for Q4 2025, filed 27 Jan 2026.